Negative regulation by PD-L1 during drug-specific priming of IL-22-secreting T cells and the influence of PD-1 on effector T cell function

Journal of Immunology

Volumn 192, Issue 6, 2014, Pages 2611-2621

  Gibson, Andrew ^a   Ogese, Monday ^a   Sullivan, Andrew ^a   Wang, Eryi ^a   Saide, Katy ^a   Whitaker, Paul ^b   Peckham, Daniel ^b   Faulkner, Lee ^a   Park, B Kevin ^a   Naisbitt, Dean J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR4; CONJUGATED LINOLEIC ACID; CUTANEOUS T CELL ATTRACTING CHEMOKINE; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 13; INTERLEUKIN 22; INTERLEUKIN 5; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE ACTIVATION; YOUNG ADULT;

ADULT; ANTI-BACTERIAL AGENTS; ANTIGENS, CD274; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; FLOXACILLIN; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-13; INTERLEUKIN-2; INTERLEUKIN-5; INTERLEUKINS; LYMPHOCYTE ACTIVATION; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN BINDING; SULFAMETHOXAZOLE; YOUNG ADULT;

EID: 84897483973     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302720     Document Type: Article

References (39)

1. Phillips, E. J., W. H. Chung, M. Mockenhaupt, J. C. Roujeau, and S. A. Mallal. 2011. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J. Allergy Clin. Immunol. 127: S60-S66.
2. Daly, A. K. 2012. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacol. Toxicol. 52: 21-35.
3. Nassif, A., A. Bensussan, G. Dorothée, F. Mami-Chouaib, N. Bachot, M. Bagot, L. Boumsell, and J. C. Roujeau. 2002. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 118: 728-733.
4. Castrejon, J. L., N. Berry, S. El-Ghaiesh, B. Gerber, W. J. Pichler, B. K. Park, and D. J. Naisbitt. 2010. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J. Allergy Clin. Immunol. 125: 411-418, e4.
5. Kuechler, P. C., M. Britschgi, S. Schmid, Y. Hari, B. Grabscheid, and W. J. Pichler. 2004. Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy 59: 613-622.
6. Monshi, M. M., L. Faulkner, A. Gibson, R. E. Jenkins, J. Farrell, C. J. Earnshaw, A. Alfirevic, K. Cederbrant, A. K. Daly, N. French, et al. 2013. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 57: 727-739.
7. Mennicke, M., A. Zawodniak, M. Keller, L. Wilkens, N. Yawalkar, F. Stickel, A. Keogh, D. Inderbitzin, D. Candinas, and W. J. Pichler. 2009. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am. J. Transplant. 9: 2197-2202.
8. Descamps, V., A. Valance, C. Edlinger, A. M. Fillet, M. Grossin, B. Lebrun-Vignes, S. Belaich, and B. Crickx. 2001. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch. Dermatol. 137: 301-304.
9. Picard, D., B. Janela, V. Descamps, M. D'Incan, P. Courville, S. Jacquot, S. Rogez, L. Mardivirin, H. Moins-Teisserenc, A. Toubert, et al. 2010. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci. Transl. Med. 2: 46ra62.
10. Engler, O. B., I. Strasser, D. J. Naisbitt, A. Cerny, and W. J. Pichler. 2004. A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. Toxicology 197: 47-56.
11. Faulkner, L., K. Martinsson, A. Santoyo-Castelazo, K. Cederbrant, I. Schuppe-Koistinen, H. Powell, J. Tugwood, D. J. Naisbitt, and B. K. Park. 2012. The development of in vitro culture methods to characterize primary T-cell responses to drugs. Toxicol. Sci. 127: 150-158.
12. Daly, A. K., P. T. Donaldson, P. Bhatnagar, Y. Shen, I. Pe'er, A. Floratos, M. J. Daly, D. B. Goldstein, S. John, M. R. Nelson, et al. 2009. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41: 816-819.
13. Schnyder, B., C. Burkhart, K. Schnyder-Frutig, S. von Greyerz, D. J. Naisbitt, M. Pirmohamed, B. K. Park, and W. J. Pichler. 2000. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J. Immunol. 164: 6647-6654.
14. Nassif, A., A. Bensussan, L. Boumsell, A. Deniaud, H. Moslehi, P. Wolkenstein, M. Bagot, and J. C. Roujeau. 2004. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114: 1209-1215.
15. Keir, M. E., L. M. Francisco, and A. H. Sharpe. 2007. PD-1 and its ligands in Tcell immunity. Curr. Opin. Immunol. 19: 309-314.
16. Okazaki, T., and T. Honjo. 2007. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19: 813-824.
17. Yokosuka, T., M. Takamatsu, W. Kobayashi-Imanishi, A. Hashimoto-Tane, M. Azuma, and T. Saito. 2012. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209: 1201-1217.
18. Gianchechi, E., D. V. Delfino, and A. Fierbracci. 2013. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun. Rev. 12: 1091-1100.
19. Zinselmeyer, B. H., S. Heydari, C. Sacristán, D. Nayak, M. Cammer, J. Herz, X. Cheng, S. J. Davis, M. L. Dustin, and D. B. McGavern. 2013. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J. Exp. Med. 210: 757-774.
20. Dyavar Shetty, R., V. Velu, K. Titanji, S. E. Bosinger, G. J. Freeman, G. Silvestri, and R. R. Amara. 2012. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J. Clin. Invest. 122: 1712-1716.
21. Duraiswamy, J., C. C. Ibegbu, D. Masopust, J. D. Miller, K. Araki, G. H. Doho, P. Tata, S. Gupta, M. J. Zilliox, H. I. Nakaya, et al. 2011. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J. Immunol. 186: 4200-4212.
22. Zelinskyy, G., L. Myers, K. K. Dietze, K. Gibbert, M. Roggendorf, J. Liu, M. Lu, A. R. Kraft, V. Teichgräber, K. J. Hasenkrug, and U. Dittmer. 2011. Virusspecific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J. Immunol. 187: 3730-3737.
23. Reiley, W. W., S. Shafiani, S. T. Wittmer, G. Tucker-Heard, J. J. Moon, M. K. Jenkins, K. B. Urdahl, G. M. Winslow, and D. L. Woodland. 2010. Distinct functions of antigen-specific CD4 T cells during murine Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. USA 107: 19408-19413.
24. Brown, J. A., D. M. Dorfman, F. R. Ma, E. L. Sullivan, O. Munoz, C. R. Wood, E. A. Greenfield, and G. J. Freeman. 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170: 1257-1266.
25. Riley, J. L. 2009. PD-1 signaling in primary T cells. Immunol. Rev. 229: 114-125.
26. Butte, M. J., M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122.
27. Callan, H. E., R. E. Jenkins, J. L. Maggs, S. N. Lavergne, S. E. Clarke, D. J. Naisbitt, and B. K. Park. 2009. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem. Res. Toxicol. 22: 937-948.
28. Naisbitt, D. J., S. J. Hough, H. J. Gill, M. Pirmohamed, N. R. Kitteringham, and B. K. Park. 1999. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br. J. Pharmacol. 126: 1393-1407.
29. Rieder, M. J., J. Uetrecht, N. H. Shear, and S. P. Spielberg. 1988. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J. Pharmacol. Exp. Ther. 244: 724-728.
30. Jenkins, R. E., X. Meng, V. L. Elliott, N. R. Kitteringham, M. Pirmohamed, and B. K. Park. 2009. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin. Appl. 3: 720-729.
31. Wuillemin, N., J. Adam, S. Fontana, S. Krähenbühl, W. J. Pichler, and D. Yerly. 2013. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J. Immunol. 190: 4956-4964.
32. Pichler, W. J. 2003. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139: 683-693.
33. Pichler, W. J., N. Yawalkar, M. Britschgi, J. Depta, I. Strasser, S. Schmid, P. Kuechler, and D. J. Naisbitt. 2002. Cellular and molecular pathophysiology of cutaneous drug reactions. Am. J. Clin. Dermatol. 3: 229-238.
34. Schnyder, B., K. Frutig, D. Mauri-Hellweg, A. Limat, N. Yawalkar, and W. J. Pichler. 1998. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin. Exp. Allergy 28: 1412-1417.
35. Elsheikh, A., L. Castrejon, S. N. Lavergne, P. Whitaker, M. Monshi, H. Callan, S. El-Ghaiesh, J. Farrell, W. J. Pichler, D. Peckham, et al. 2011. Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole- hypersensitive patients with cystic fibrosis. J. Allergy Clin. Immunol. 127: 1543-1551, e3.
36. Boniface, K., F. X. Bernard, M. Garcia, A. L. Gurney, J. C. Lecron, and F. Morel. 2005. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 174: 3695-3702.
37. Cavani, A., D. Pennino, and K. Eyerich. 2012. Th17 and Th22 in skin allergy. Chem. Immunol. Allergy 96: 39-44.
38. Eyerich, S., K. Eyerich, A. Cavani, and C. Schmidt-Weber. 2010. IL-17 and IL-22: siblings, not twins. Trends Immunol. 31: 354-361.
39. Akdis, M., O. Palomares, W. van de Veen, M. van Splunter, and C. A. Akdis. 2012. TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection. J. Allergy Clin. Immunol. 129: 1438-1449, z1450-z1451.